Form 4: Tharimmune Director Lynne A. Bui Acquires Options in Company Stock

Director Lynne A. Bui was granted options to purchase 2,353 shares of Tharimmune, Inc. common stock on August 9, 2024, under the company's 2023 Omnibus Equity Incentive Plan.

Summary

• On August 9, 2024, Lynne A. Bui, a director of Tharimmune, Inc., was granted options to purchase 2,353 shares of the company's common stock.
• The options were granted pursuant to the company's 2023 Omnibus Equity Incentive Plan.
• The exercise price of the options is $2.925.
• The options vest in 12 equal monthly installments, beginning on the grant date, and expire on August 9, 2034.
• Following the transaction, Ms. Bui directly owns 27,353 shares of Tharimmune, Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of options is a standard practice and aligns the director's interests with shareholders. There are no explicit negative implications.

Positives

• The grant of options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Future Outlook

This Form 4 filing reflects standard equity compensation practices and doesn't provide specific forward-looking statements about the company's performance.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain talent, aligning management's interests with those of shareholders. This grant is part of Tharimmune's overall compensation strategy.

Comparison to Industry Standards

• Equity grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead, and Biogen also utilize stock options and restricted stock units as part of their compensation packages for directors and executives.
• The vesting schedule of 12 months is fairly typical, aligning with industry norms for incentivizing long-term commitment.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to incentivizing its leadership.

Key Dates

Keywords

Form 4, Beneficial Ownership, Director, Options, THAR, Tharimmune, Inc., Equity Incentive Plan, Lynne A. Bui